SCHEMBL1305053

SCHEMBL1305053

CC(NC(N)=O)(C(=O)O)C(Oc1ccccc1)c1ccc(C(Oc2ccccc2)C(C)(NC(N)=O)C(=O)O)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.37
ALOX5 P09917 1/20 0.37
LMNA P02545 2/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
GLA P06280 1/20 0.35
ALDH1A1 P00352 4/20 0.35
CNR2 P34972 1/20 0.35
TSHR P16473 1/20 0.34
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
ACACB O00763 1/20 0.33
ACACA Q13085 1/20 0.33
CRHBP P24387 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12468591 0.80 ALDH1A1 (0.43) POLBLMNAATML3MBTL1MTNR1A
SCHEMBL3745853 0.67 CYP2D6 (0.41) POLBLMNAATMMTNR1AMTNR1B
SCHEMBL5309684 0.66 ALPL (0.44) POLBLMNAL3MBTL1MTNR1AMTNR1B
SCHEMBL8695089 0.65 ATM (0.45) POLBALOX5LMNAATML3MBTL1
SCHEMBL82057 0.63 MTNR1A (0.45) POLBLMNAATML3MBTL1MTNR1A
SCHEMBL27671316 0.63 POLB (0.60) POLBATMMEN1KMT2AALDH1A1
SCHEMBL22100068 0.63 HPGD (0.56) POLBATMMEN1KMT2ATSHR
SCHEMBL7750587 0.63 POLB (0.46) POLBLMNAMTNR1AMTNR1BMEN1
SCHEMBL7322928 0.62 ATM (0.49) LMNAATML3MBTL1MTNR1AMTNR1B
SCHEMBL28376940 0.62 MAPT (0.55) LMNAKMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048896-B2 Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors Cell Viable Corporation (US) 2011-11-01 US claimed
US-6605642-B2 Administering specified compounds which are derivatives of phenoxyisobutyric acids and of benzoic acid including aryl and heterocyclic ureido derivatives and aryl and heterocyclic carboxamido derivatives; treating aging, arthritis, diabetes CITY OF HOPE 2003-08-12 US claimed
US-8053449-B2 Method for inhibiting AGE complex formation Cell Viable Corporation (US) 2011-11-08 US disclosed
US-8048896-B2 Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors Cell Viable Corporation (US) 2011-11-01 US disclosed
US-20080076804-A1 METHODS FOR INHIBITING AND BREAKING AGE COMPLEX FORMATION Cell Viable Corporation 2008-03-27 US disclosed
US-20070099966-A1 Device and Method for Inhibiting AGE Complex Formation Cell Viable Corporation 2007-05-03 US disclosed